Cystic fibrosis (CF) is caused by mutations in the cystic fibrosis transmembrane regulator gene (CFTR). In light of the strong allelic heterogeneity and regional specificity of the mutation spectrum, the strategy of molecular diagnostics and counseling in CF requires genetic tests to reflect the frequency profile characteristic for a given population. The goal of the study was to provide an updated comprehensive estimation of the distribution of CFTR mutations in Polish CF patients and to assess the effectiveness of INNOLiPA_CFTR tests in Polish population. The analyzed cohort consisted of 738 patients with the clinically confirmed CF diagnosis, prescreened for molecular defects using INNOLiPA_CFTR panels from Innogenetics. A combined efficiency of INNOLiPA CFTR_19 and CFTR_17_TnUpdate tests was 75.5%; both mutations were detected in 68.2%, and one mutation in 14.8% of the affected individuals. The group composed of all the patients with only one or with no mutation detected (109 and 126 individuals, respectively) was analyzed further using a mutation screening approach, i.e. SSCP/HD (single strand conformational polymorphism/heteroduplex) analysis of PCR products followed by sequencing of the coding sequence. As a result, 53 more mutations were found in 97 patients. The overall efficiency of the CF allele detection was 82.5% (7.0% increase compared to INNOLiPA tests alone). The distribution of the most frequent mutations in Poland was assessed. Most of the mutations repetitively found in Polish patients had been previously described in other European populations. The most frequent mutated allele, F508del, represented 54.5% of Polish CF chromosomes. Another eight mutations had frequencies over 1%, 24 had frequencies between 1 and 0.1%; c.2052-2053insA and c.3468+2_3468+3insT were the most frequent non-INNOLiPA mutations. Mutation distribution described herein is also relevant to the Polish diaspora. Our study also demonstrates that the reported efficiency of mutation detection strongly depends on the diagnostic experience of referring health centers.
References
[1]
Southern KW, Munck A, Pollitt R, Travert G, Zanolla R, et al. (2007) ECFS CF Neonatal Screening Working Group. A survey of newborn screening for cystic fibrosis in Europe. J Cyst Fibros 6: 57–65. doi: 10.1016/j.jcf.2006.05.008
[2]
Farrell PM (2008) The prevalence of cystic fibrosis in the European Union. J Cyst Fibros 7: 450–453. doi: 10.1016/j.jcf.2008.03.007
[3]
Kerem B-S, Rommens JM, Buchanan JA, Markiewicz D, Cox TK, et al. (1989) Identification of the cystic fibrosis gene: genetic analysis. Science 245: 1073–80. doi: 10.1126/science.2570460
[4]
Estivill X, Bancells C, Ramos C (1997) Geographic distribution and regional origin of 272 cystic fibrosis mutations in European populations. The Biomed CF Mutation Analysis Consortium. Hum Mutat 10: 135–54. doi: 10.1002/(sici)1098-1004(1997)10:2<135::aid-humu6>3.0.co;2-j
[5]
Bobadilla JL, Macek M Jr, Fine JP, Farrel PM (2002) Cystic Fibrosis: A worldwide analysis of CFTR mutations-correlation with incidence data and application to screening. Hum Mutat 19: 575–606. doi: 10.1002/humu.10041
[6]
Dequeker E, Stuhrmann M, Morris MA, Casals T, Castellani C, et al. (2009) Best practice guidelines for molecular genetic diagnosis of cystic fibrosis and CFTR-related disorders—updated European recommendations. Eur J Hum Genet 17: 51–65. doi: 10.1038/ejhg.2008.136
[7]
Aznarez I, Bal J, Casals T, Estivill X, Moral N, et al. (2000) Analysis of mutations in the CFTR gene in patients diagnosed with cystic fibrosis in Poland (in Polish). Med Wieku Rozwoj 4: 149–59.
[8]
Bal J, Maciejko D, Mazurczak T, Potocka A, Krawczak M, et al. (1991) Frequency of the cystic fibrosis mutation delta F508 in Poland. Hum Genet 86: 329. doi: 10.1007/bf00202424
[9]
Bal J, Maciejko D, Mazurczak T (1995) The type and frequency of mutations in CFTR gene occurrence in patients with cystic fibrosis in Poland - implication of results obtained from genetic counseling and diagnostic screening (in Polish). Pediatr Pol 70: 627–32.
[10]
Witt M, Pogorzelski A, Bal J, Rutkiewicz E, Majka L, et al. (1999) Frequency of mutations and genotypes of the CFTR gene in cystic fibrosis adults in Poland (in Polish). Pneumonol Alergol Pol 67: 137–41.
[11]
Zietkiewicz E, Nitka B, Voelkel K, Skrzypczak U, Bukowy Z, et al. (2010) Population specificity of the DNAI1 gene mutation spectrum in primary ciliary dyskinesia (PCD). Respir Res 11: 174. doi: 10.1186/1465-9921-11-174
[12]
Castellani C, Cuppens H, Macek Jr M, Cassiman JJ, Kerem E, et al. (2008) Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. J Cyst Fibros 7: 179–96. doi: 10.1016/j.jcf.2008.03.009
[13]
Bo？kowa E, Golebiowska H, Rutkowski J, Nowakowska A, Holzer J (1971) Epidemiologia mukowiscydozy u dzieci w Polsce (in Polish). Ped Pol 46: 677–684.
[14]
Colombo C, Littlewood J (2011) The implementation of standards of care in Europe: state of the art. J Cyst Fibros 10S2: S7–15.
[15]
WHO Report (2004) The molecular genetic epidemiology of cystic fibrosis; www.who.int/genomics/publications/en/HGN？_WB_04.02_report.pdf.
[16]
S？uszniak A, Kurtyka Z, Lemańska D (2011) Neonatal mass screening for cystic fibrosis in south-east Poland (in Polish). Przegl Lek 68: 59–62.
[17]
Kerem E, Corey M, Kerem B, Durie P, Tsui LC, et al. (1989) Clinical and genetic comparisons of patients with cystic fibrosis, with or without meconium ileus. J Pediatr 114: 767–73. doi: 10.1016/s0022-3476(89)80134-9
[18]
Fakhoury K, Durie PR, Levison H, Canny GJ (1992) Meconium ileus in the absence of cystic fibrosis. Arch Dis Child 67s: 1204–6. doi: 10.1136/adc.67.10_spec_no.1204
[19]
Gorter RR, Karimi A, Sleeboom C, Kneepkens CM, Heij HA (2010) Clinical and genetic characteristics of meconium ileus in newborns with and without cystic fibrosis. J Pediatr Gastroenterol Nutr 50: 569–72. doi: 10.1097/mpg.0b013e3181bb3427
[20]
Grody W, Cutting G, Klinger K, Richards CS, Watson MS, et al. (2001) Laboratory standards and guidelines for population-based cystic fibrosis carrier screening. Genet Med 3: 149–54. doi: 10.1097/00125817-200103000-00010
[21]
Krenkova P, Piskackova T, Holubova A, Balascakova M, Krulisova V, et al. (2012) Distribution of CFTR mutations in the Czech population: Positive impact of integrated clinical and laboratory expertise, detection of novel/de novo alleles and relevance for related/derived populations. J Cyst Fibros S: 1569–1993.
[22]
Dork T, Mekus F, Schmidt K, Bosshammer J, Fislage R, et al. (1994) Detection of more than 50 different CFTR mutations in a large group of German cystic fibrosis patients. Hum Genet 94: 533–42. doi: 10.1007/bf00211022
[23]
Giannattasio S, Bobba A, Jurgelevicius V, Vacca RA, Lattanzio P, et al. (2006) Molecular basis of cystic fibrosis in Lithuania: incomplete CFTR mutation detection by PCR-based screening protocols. Genet Test 10: 169–73. doi: 10.1089/gte.2006.10.169
[24]
Makukh H, Krenkova P, Tyrkus M, Bober L, Hancarova M, et al. (2010) A high frequency of the cystic fibrosis 2184insA mutation in Western Ukraine: genotype–phenotype correlations, relevance for newborn screening and genetic testing. J Cyst Fibros 9: 371–5. doi: 10.1016/j.jcf.2010.06.001
[25]
Ivady G, Madar L, Nagy B, Gonczi F, Ajzner E, et al. (2011) Distribution of CFTR mutations in Eastern Hungarians: relevance to genetic testing and to the introduction of newborn screening for cystic fibrosis. J Cyst Fibros 10: 217–20. doi: 10.1016/j.jcf.2010.12.009
[26]
Frentescu L, Brownsell E, Hinks J, Malone G, Shaw H, et al. (2008) The study of cystic fibrosis transmembrane conductance regulator gene mutations in a group of patients from Romania. J Cyst Fibros 7: 423–8. doi: 10.1016/j.jcf.2008.03.004
[27]
Angelicheva D, Calafell F, Savov A, Jordanova A, Kufardjieva A, et al. (1997) Cystic fibrosis mutations and associated haplotypes in Bulgaria – a comparative population genetic study. Hum Genet 99: 513–520. doi: 10.1007/s004390050398
[28]
Radivojevic D, Djurisic M, Lalic T, Guc-Scekic M, Savic J, et al. (2004) Spectrum of cystic fibrosis mutations in Serbia and Montenegro and strategy for prenatal diagnosis. Genet Test 8: 276–280. doi: 10.1089/gte.2004.8.276
[29]
Kanavakis E, Efthymiadou A, Strofalis S, Doudounakis S, Traeger-Synodinos J, et al. (2003) Cystic fibrosis in Greece: molecular diagnosis, haplotypes, prenatal diagnosis and carrier identyfication amongst high-risk individuals. Clin Genet 63: 400–409. doi: 10.1034/j.1399-0004.2003.00067.x
[30]
Dork T, Macek Jr M, Mekus F, Tummler B, Tzountzouris J, et al. (2000) Characterization of a novel 21-kb deletion, CFTRdele2,3(21kb), in the CFTR gene: a cystic fibrosis mutation of Slavic origin common in Central and East Europe. Hum Genet 106: 259–68. doi: 10.1007/s004390000246
[31]
Cuppens H, Lin W, Jaspers M, Costes B, Teng H, et al. (1998) Polyvariant mutant cystic fibrosis transmembrane conductance regulator genes – the polymorphic (TG)m locus explains the partial penetrance of the T5 polymorphism as a disease mutation. J Clin Invest 101: 487–496. doi: 10.1172/jci639
[32]
Groman JD, Hefferon TW, Casals T, Bassas L, Estivill X, et al. (2004) Variation in a repeat sequence determines whether a common variant of the cystic fibrosis transmembrane conductance regulator gene is pathogenic or benign. Am J Hum Genet 74: 176–9. doi: 10.1086/381001
[33]
Rosenstein BJ, Cutting GR (1998) The diagnosis of cystic fibrosis: a consensus statement. J Pediatr 132: 589–595. doi: 10.1016/s0022-3476(98)70344-0
[34]
Traeger N, Shi Q, Dozor AJ (2013) Relationship between sweat chloride, sodium, and age in clinically obtained samples. J Cyst Fibros S1: 569–1933. doi: 10.1016/j.jcf.2013.07.003
[35]
Heaney DL, Flume P, Hamilton L, Lyon E, Wolff DJ (2006) Detection of an apparent homozygous 3120G>A cystic fibrosis mutation on a routine carrier screen. J Molec Diagn 8: 137–140. doi: 10.2353/jmoldx.2006.050065
